U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Ifon, Ekwere T ^a   Pang, Alan L Y ^b   Johnson, Warren ^b   Cashman, Kathleen ^a   Zimmerman, Sharon ^a   Muralidhar, Sumitra ^a   Chan, Wai Yee ^a,b   Casey, John ^a   Rosenthal, Leonard Jason ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN LIKE AND METALLOPROTEASE; ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; COMPLEMENTARY DNA; FIBRONECTIN; FIBRONECTIN 1; MESSENGER RNA; METALLOPROTEINASE; PLASMID DNA; PLASMID VECTOR; PROTEIN U94; SERINE PROTEINASE; SERINE PROTEINASE 23; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 2; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRAL GENE THERAPY;

EID: 26844516667     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-5-19     Document Type: Article

References (79)

1. American Cancer Society: Cancer Statistics Presentation. [http://www.cancer.org/docroot/STT/stt_0_2004.asp?sitearea= STT&level=1
2. Ficazzola MA, Taneja SS: Prospects for gene therapy in human prostate cancer. Molecular Medicine Today 1998, 4:494-504.
3. Buttyan R, Shabsigh A, Perlman H, Colombel M: Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids. Trends Endocrinol Metab 1999, 10:47-54.
4. Chakravarti A, Zhai GG: Molecular and genetic prognostic factors of prostate cancer. World J Urol 2003, 21:265-274.
5. Karan D, Lin M, Johansson SL, Batra SK: Current Status of the Molecular Genetics of Human Prostatic Adenocarcinomas. Int J Cancer 2003, 103:285-293.
6. Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes and Dev 2000, 14:2410-2434.
7. Kumazawa T, Tsuchiya N, Wang L, Sato K, Kamoto T, Ogawa O, Nakamura A, Kato T, Habuchi T: Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer 2004, 110:140-144.
8. Flaherty KT, Malkowicz SB, Vaughn DJ: Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. Am J Clin Oncol 2004, 27:136-139.
9. Joshi B, Li L, Taffe BG, Zhu Z, Wahl S, Tian H, Ben-Josef E, Taylor JD, Porter AT, Tang DG: Apoptosis Induction by a Novel Anti-Prostate Cancer Compound, BMD188 (a Fatty Acid-containing Hydroxamic Acid), Requires the Mitochondrial Respiratory Chain. Cancer Res 1999, 59:4343-4355.
10. Goodin S, Rao KV, DiPaola RS: State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer. Oncologist 2002, 7:360-370.
11. Gulley J, Dahut W: Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002, 1:51-57.
12. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN: Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor- related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels. Cancer Res 2001, 61:759-763.
13. Chay CH, Cooper CC, Hellerstedt BA, Pienta KJ: Antimetastatic drugs in prostate cancer. Clin Prostate Cancer 2002, 1:14-19.
14. Allay JA, Steiner MS, Zhang Y, Reed CP, Cockroft J, Lu Y: Adenovirus p16 gene therapy for prostate cancer. World J Urol 2000, 18:111-120.
15. Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W: National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer 2002, 1:153-162.
16. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS: Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002, 62:1370-1376.
17. Steiner MS, Wang Y, Zhang Y, Zhang X, Lu Y: p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 2000, 19:1297-1306.
18. Sternberg C: Overview of international collaborative group prostate cancer trials. Crit Rev Oncol Hematol 2002, 43:153-158.
19. Collis SJ, Khater K, DeWeese TL: Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol 2003, 21:275-289.
20. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC: Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 2003, 4:251-261.
21. Thompson BJ, Efstathiou S, Honess RW: Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6. Nature 1991, 351:78-80.
22. Araujo JC, Doniger J, Kashanchi F, Hermonat PL, Thompson J, Rosenthal LJ: Human Herpesvirus 6A suppresses both transformations by H-ras and Human Immunodeficiency Virus type 1 promoters. J Virol 1995, 69:4933-4940.
23. Mori Y, Dhepakson P, Shimamoto T, Ueda K, Gomi Y, Tani H, Matsuura Y, Yamanishi K: Expression of human herpesvirus 6B rep within infected cells and binding of its gene product to the TATA-Binding protein in vitro and in vivo. J Virol 2000, 74:6096-6104.
24. Dhepakson P, Mori Y, Jiang YB, Huang HL, Akkapaiboon P, Okuno T, Yamanishi K: Human herpesvirus-6 rep/U94 gene product has single-stranded DNA-binding activity. J Gen Virol 2002, 83:847-854.
25. Rotola A, Ravaioli T, Gonelli A, Dewhurst S, Cassai E, Di Luca D: U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture. Proc Natl Acad Sci USA 1998, 95:13911-13916.
26. Turner S, DiLuca D, Gompels UA: Characterization of a human herpesvirus 6 variant A 'amplicon' and replication modulation by U94-Rep 'latency gene'. Journal of Virological Methods 2002, 105:331-341.
27. Gompels UA, Nicholas J, Lawrence G, Jones M, Thomson BJ, Martin ME, Efstathiou S, Craxton M, Macaulay HA: The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 1995, 209:29-51.
28. Thomson BJ, Weindler FW, Gray D, Schwaab V, Heilbronn R: Human herpesvirus 6 (HHV-6) is a helper virus for adeno-associated virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can mediate AAV-2 DNA replication and regulate gene expression. Virology 1994, 204:304-311.
29. Araujo JC, Doniger J, Stöppler H, Sadaie MR, Rosenthal LJ: Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation. Oncogene 1997, 14:937-943.
30. Kibel AS, Faith DA, Bova GS, Isaacs WB: Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol 2000, 164:192-196.
31. Guo Y, Sklar GN, Borkowski A, Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997, 3:2269-2274.
32. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998, 58:542-548.
33. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945.
34. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A: p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999, 96:6382-6387.
35. Chi SG, deVere White RW, Muenzer JT, Gumerlock PH: Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997, 3:1889-1897.
36. Jarrard D, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze S, Friedl A: Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002, 185:191.
37. Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA: p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 1999, 59:2957-2964.
38. Alexander K, Hinds PW: Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol 2001, 21:3616-3631.
39. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993, 143:390-400.
40. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC: Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Brit J Cancer 1996, 74:1258-1262.
41. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of Bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996, 2:389-398.
42. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ: Expression of bcl-2 oncoprotein and p53 protein accumulaion in bone marrow metastases of androgen independent prostate cancer. J Urol 1997, 157:569-574.
43. Chaudhary KS, Abel PD, Lalani EN: Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999, 107(Suppl 1): 49-57.
44. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987, 11:327-337.
45. Phillips MEA, Ferro MA, Smith PJB, Davies P: Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. Urol Int 1987, 42:115-119.
46. Nag A, Smith RG: Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. Prostate 1989, 15:115-122.
47. Peehl DM: Oncogenes in Prostate Cancer. Cancer 1993, 71:1159-1164.
48. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826.
49. Muralidhar S, Doniger J, Mendelson E, Araujo JC, Kashanchi F, Azumi N, Brady JN, Rosenthal LJ: Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J Virol 1996, 70:8691-8700.
50. Le-Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Siboney M, Gasc JM, Corvol P, Germain S: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003, 162:1521-1528.
51. Yi M, Ruoslahti E: A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA 2001, 98:620-624.
52. Zhang GM, Yang Y, Huang B, Xiao H, Li D, Feng ZH: Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma. World J Gastroenterol 2003, 9:1940-1945.
53. Yi M, Sakai T, Fassler R, Ruoslahti E: Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA 2003, 100:11435-11438.
54. Pasqualini R, Bourdoulous S, Koivunen E, Woods VL Jr, Ruoslahti EA: Polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996, 2:1197-1203.
55. Hynes RO: The dynamic dialogue between cells and matrices: implications of fibronectin's elasticity. Proc Natl Acad Sci USA 1999, 96:2588-2590.
56. Schwarzbauer JE: Identification of the fibronectin sequences required for assembly of a fibrillar matrix. J Cell Biol 1991, 113:1463-1473.
57. Hocking DC, Sottile J, McKeown-Longo PJ: Fibronectin's III-I module contains a conformation-dependent binding site for the amino-terminal region of fibronectin. J Biol Chem 1994, 269:19183-19191.
58. Aguirre KM, McCormick RJ, Schqarzbauer JE: Fibronectin selfassociation is mediated by complementary sites within the amino-terminal one-third of the molecule. J Biol Chem 269:27863-27868.
59. Briknarovà K, Åkerman ME, Hoyt DW, Ruoslahti E, Ely KR: Anastellin, an FN 3 Fragment with Fibronectin Polymerization Acitivity, Resembles Amyloid Fibril Precursors. J Mol Biol 2003, 332:205-215.
60. 2F2 fragment from human fibronectin enhances gelatin binding. The EMBO Journal 2001, 20:1519-1529.
61. Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science 1995, 268:233-239.
62. Brenner KA, Corbett SA, Schwarzbauer JE: Regulation of fibronectin matrix assembly by activated Ras in transformed cells. Oncogene 2000, 19:3156-3163.
63. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
64. Risau W: Mechanism of angiogenesis. Nature 1997, 386:671-674.
65. Varner JA: The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS 1997, 79:361-90.
66. Ruoslahti e: The RGD story: a personal account. Matrix Biology 2003, 22:459-465.
67. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002, 8:918-921.
68. Vitale M, Matola TD, Rossi G, Laezza C, Fenzi G, Bifulco M: Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-Independent, CrmA-Sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology 1999, 140:698-704.
69. Kuno K, Terashima Y, Matsushima K: ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J Biol Chem 1999, 274:18821-18826.
70. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K: ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest 2000, 105:1345-1352.
71. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML: METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999, 274:23349-23357.
72. Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen W: Identification of the 170-kDa Melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997, 272:7595-7601.
73. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, Tanghetti E, Dammacco F: alpha (v) beta (3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001, 29:993-1003.
74. Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P, Wang N: THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genetics and Cytogenetics 2002, 143:125-132.
75. Rapp JC, Krug LT, Inoue N, Dambaugh TR, Pellett PE: U94 the human herpesvirus 6 homolog of the Parvovirus nonstructural gene, is highly conserved among isolates and is expressed at low mRNA levels as a spliced transcript. Virology 2000, 268:504-516.
76. Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA: Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia 2001, 3:62-69.
77. Olnes MI, Kurl RN: Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques 1994, 17:828-829.
78. Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Kishishita M, Brady JN, Doniger J, Medveczky P, Rosenthal LJ: Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol 1998, 72:4980-4988.
79. Pang AL, Taylor HC, Johnson W, Alexander S, Chen Y, Su YA, Li X, Ravindranath N, Dvm M, Rennert OM, Chan WY: Identification of differentially expressed genes in mouse spermatogenesis. J Androl 2003, 24:899-911.